Seelos Therapeutics Announces Closing of Public Offering of Common Stock
2020年3月17日 - 5:30AM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today the closing of its previously announced underwritten public
offering of 7,500,000 shares of its common stock, at a price to the
public of $0.60 per share. The net proceeds to Seelos from this
offering are expected to be approximately $3.9 million, after
deducting underwriting discounts and commissions and other
estimated offering expenses payable by Seelos. Seelos intends to
use the net proceeds from the offering for general corporate
purposes and to advance the development of its product candidates.
Benchmark Company acted as sole book-running manager for the
offering.
The securities described above were offered by Seelos pursuant
to a “shelf” registration statement on Form S-3 (File No.
333-221285) previously filed with the Securities and Exchange
Commission (the “SEC”) on November 2, 2017, amended on December 1,
2017 and declared effective by the SEC on December 7, 2017. A
final prospectus supplement and the accompanying prospectus
relating to and describing the offering was filed with the SEC.
Electronic copies of the final prospectus supplement and the
accompanying prospectus may be obtained by visiting the SEC’s
website at www.sec.gov or by contacting The Benchmark Company, LLC,
Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New
York, NY 10155, by calling (212) 312-6700 or by e-mail at
prospectus@benchmarkcompany.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel therapeutics
to address unmet medical needs in central nervous system (CNS)
disorders and other rare orphan disorders. The Company's robust
portfolio includes several late-stage clinical assets. The target
indications include Acute Suicidal Ideation and Behavior (ASIB) in
Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder
(PTSD), Sanfilippo syndrome, Parkinson’s Disease and other
psychiatric and movement disorders.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward-Looking Statements:
This press release contains forward-looking statements related
to Seelos Therapeutics, Inc. and its subsidiaries under the safe
harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995 and subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Forward-looking statements include statements
regarding the amount and anticipated use of proceeds from the
offering and other matters that are described in Seelos’ most
recent periodic reports filed with the SEC, including Seelos’
Annual Report on Form 10-K for the year ended December 31, 2018
filed on March 28, 2019, subsequent Quarterly Reports on Form 10-Q
and the final prospectus supplement and the accompanying prospectus
related to the public offering filed with the SEC on March 12,
2020, including risks and uncertainties associated with general
economic and market conditions and the other risk factors set forth
in those filings. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release and Seelos disclaims any intent or
obligation to update these forward-looking statements except as
required by law.
Contact Information: Anthony Marciano Head of
Corporate Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 9 2024 まで 10 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 10 2023 まで 10 2024